BioSkryb: Gary Harton

Jun 30, 2021

BioSkryb, a Durham, North Carolina-based developer of genomic amplification technologies, has appointed Gary Harton as CSO. Harton has more than 30 years of experience in single-cell diagnostic product development, and will apply BioSkryb’s platform technology to develop new diagnostic technologies for cancer, neurological disorders, and assisted reproductive technologies, the company said. Prior to BioSkryb, he was the portfolio director for preimplantation genetic testing at PerkinElmer. He has also previously held a variety of product and portfolio-development positions at PerkinElmer, Igenomix US, Progyny, Illumina, BlueGnome, and Reprogenetics.

BioSkryb: Gary Harton

Diasorin Nabs FDA 510(k) Clearance for Gram-Negative Bloodstream Infection Panel

Protein Biomarkers May Predict Obese Patients at Risk of Liver Inflammation

People in the News at Tempus AI, BostonGene, Biodesix, EnPlusOne

Singleron, IHLAD Launch Middle East Joint Venture

In Brief This Week: Chromatin Bioscience, Oxford Nanopore, Thermo Fisher, More